Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

被引：0
|
作者：
Chiao-En Wu
Ching-Fu Chang
Chen-Yang Huang
Cheng-Ta Yang
Chih-Hsi Scott Kuo
Ping-Chih Hsu
John Wen-Cheng Chang
机构：
[1] Chang Gung University College of Medicine,Department of Internal Medicine, Division of Hematology
[2] Chang Gung University College of Medicine,Oncology, Chang Gung Memorial Hospital at Linkou
来源：
BMC Cancer | / 21卷
关键词：
Lung cancer; Afatinib; EGFR; TKI; Performance status;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] COMPARATIVE SAFETY PROFILE OF AFATINIB IN ASIAN AND NON-ASIAN PATIENTS WITH EGFR MUTATION-POSITIVE (EGFR M plus ) NON-SMALL CELL LUNG CANCER (NSCLC)
    Sequist, Lecia V.
    Yang, James C.
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Schuler, Martin
    Mok, Tony
    Geater, Sarayut Lucien
    Massey, Daniel
    Wind, Sven
    O'Brien, Dennis
    Lorence, Robert
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1197 - S1197
  • [32] Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression
    Hosomi, Yukio
    Tanai, Chiharu
    Yoh, Kiyotaka
    Goto, Yasushi
    Sakai, Hiroshi
    Kato, Terufumi
    Kaburagi, Takayuki
    Nishio, Makoto
    Kim, Young Hak
    Inoue, Akira
    Hasegawa, Yoshinori
    Isobe, Hiroshi
    Tomizawa, Yoshio
    Mori, Yoshiaki
    Minato, Koichi
    Yamada, Kazuhiko
    Ohashi, Yasuo
    Kunitoh, Hideo
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (10) : 1049 - 1056
  • [33] Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA
    Lim, Jonathan
    Samuelsen, Carl
    Golembesky, Amanda
    Shrestha, Sulena
    Wang, Li
    Griebsch, Ingolf
    FUTURE ONCOLOGY, 2019, 15 (13) : 1493 - 1504
  • [34] Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small-cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22
    Jung, Hyun Ae
    Hong, Min Hee
    Lee, Hyun Woo
    Lee, Kyung Hee
    Kim, Il Hwan
    Min, Young Joo
    Ahn, Hee Kyung
    Shim, Byoung Yong
    Choi, Yoon Hee
    Lee, Yun-Gyoo
    Kim, Jeong A.
    Jang, Joung Soon
    Shin, Seong-Hoon
    Park, Keon Uk
    Kang, Jin Hyoung
    Park, Keunchil
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (07) : 1369 - +
  • [35] Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study
    Brueckl, Wolfgang M.
    Reck, Martin
    Schaefer, Harald
    Neben, Kai
    Griesinger, Frank
    Rawluk, Justyna
    Krueger, Stefan
    Kokowski, Konrad
    Ficker, Joachim H.
    Moeller, Miriam
    Schueler, Andrea
    Laack, Eckart
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (01)
  • [36] Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer
    Corral, Jesus
    Mok, Tony S.
    Nakagawa, Kazuhiko
    Rosell, Rafael
    Lee, Ki Hyeong
    Migliorino, Maria Rita
    Pluzanski, Adam
    Linke, Rolf
    Devgan, Geeta
    Tan, Weiwei
    Quinn, Susan
    Wang, Tao
    Wu, Yi-Long
    FUTURE ONCOLOGY, 2019, 15 (24) : 2795 - 2805
  • [37] First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
    Park, Keunchil
    Lim, Darren Wan-Teck
    Okamoto, Isamu
    Yang, James Chih-Hsin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [38] Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Kimura, M.
    Yasue, F.
    Usami, E.
    Kawachi, S.
    Iwai, M.
    Go, M.
    Ikeda, Y.
    Yoshimura, T.
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (02) : 201 - 206
  • [39] Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland - real-world data
    Brzozowska, Melania
    Wierzba, Waldemar
    Szafraniec-Burylo, Sylwia
    Czech, Marcin
    Majkut, Gabriela
    Polowinczak-Przybylek, Joanna
    Potemski, Piotr
    Sliwczynski, Andrzej
    ARCHIVES OF MEDICAL SCIENCE, 2021, 17 (06) : 1618 - 1627
  • [40] The Study of EGFR Mutation Specific-Antibody for Detection of EGFR Status in Non-Small Cell Lung Cancer
    Charoentum, Chaivut
    Phanthunane, Chumut
    Lertprasertsuke, Nirush
    Theerakittikul, Theerakorn
    Limsukon, Atikun
    Saeteng, Somcharoen
    Tantraworasin, Apichart
    Euathrongchit, Juntima
    Wannasopha, Yutthaphan
    Suksombooncharoen, Thatthan
    Chewaskulyong, Busyamas
    Thongprasert, Sumitra
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S589 - S589
12345